Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M88,712Revenue $M6,494Net Margin (%)21.8Z-Score6.9
Enterprise Value $M88,689EPS $1.7Operating Margin %28.5F-Score7
P/E(ttm))58.3Cash Flow Per Share $4.4Pre-tax Margin (%)25.0Higher ROA y-yN
Price/Book15.310-y EBITDA Growth Rate %0Quick Ratio6.1Cash flow > EarningsY
Price/Sales12.65-y EBITDA Growth Rate %22.2Current Ratio6.3Lower Leverage y-yN
Price/Cash Flow17.9y-y EBITDA Growth Rate %11.0ROA % (ttm)11.2Higher Current Ratio y-yY
Dividend Yield %0Insider Buy (3m)0ROE % (ttm)30.1Less Shares Outstanding y-yY
Payout Ratio %0Shares Outstanding M799ROI % (ttm)17.8Gross Margin Increase y-yY

Gurus Latest Trades with CELG

Number of guru portfolios checked: 84. (List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
CELGJohn Hussman 2014-09-30 Buy 0.2%$83.13 - $96.21
($90.29)
$ 111.0723%New holding, 25000 sh.25,000
CELGKen Fisher 2014-09-30 Add0.02%$83.13 - $96.21
($90.29)
$ 111.0723%Add 77.12%232,137
CELGGeorge Soros 2014-09-30 Sold Out -0.45%$83.13 - $96.21
($90.29)
$ 111.0723%Sold Out0
CELGJoel Greenblatt 2014-09-30 Sold Out -0.07%$83.13 - $96.21
($90.29)
$ 111.0723%Sold Out0
CELGGeorge Soros 2014-06-30 Buy 0.45%$68.45 - $86.8
($75.89)
$ 111.0746%New holding, 688000 sh.688,000
CELGJoel Greenblatt 2014-06-30 Buy 0.07%$68.45 - $86.8
($75.89)
$ 111.0746%New holding, 63980 sh.63,980
CELGKen Fisher 2014-06-30 Add0.01%$68.45 - $86.8
($75.89)
$ 111.0746%Add 75.59%131,064
CELGRonald Muhlenkamp 2014-06-30 Reduce-1.91%$68.45 - $86.8
($75.89)
$ 111.0746%Reduce -51.74%144,140
CELGRay Dalio 2014-06-30 Sold Out -0.08%$68.45 - $86.8
($75.89)
$ 111.0746%Sold Out0
CELGJohn Burbank 2014-06-30 Sold Out -0.01%$68.45 - $86.8
($75.89)
$ 111.0746%Sold Out0
CELGRay Dalio 2014-03-31 Add0.07%$69.65 - $85.97
($79.51)
$ 111.0740%Add 962.69%142,400
CELGJohn Burbank 2014-03-31 Buy 0.01%$69.65 - $85.97
($79.51)
$ 111.0740%New holding, 1670 sh.3,340
CELGKen Fisher 2014-03-31 Add0.01%$69.65 - $85.97
($79.48)
$ 111.0740%Add 1591.8%74,642
CELGJohn Keeley 2014-03-31 Sold Out $69.65 - $85.97
($79.51)
$ 111.0740%Sold Out0
CELGRonald Muhlenkamp 2013-12-31 Add0.12%$72.25 - $85.39
($79.05)
$ 111.0740%Add 2.87%294,850
CELGRay Dalio 2013-12-31 Buy 0.01%$72.25 - $85.39
($79.05)
$ 111.0740%New holding, 6700 sh.13,400
CELGJohn Keeley 2013-09-30 Buy $60.13 - $77.31
($70.14)
$ 111.0758%New holding, 1320 sh.2,640
CELGMario Gabelli 2013-09-30 Add$60.13 - $77.31
($70.14)
$ 111.0758%Add 29.5%20,940
CELGKen Fisher 2013-09-30 Reduce$60.13 - $77.31
($70.14)
$ 111.0758%Reduce -44.85%4,980
CELGJohn Hussman 2013-09-30 Sold Out -0.31%$60.13 - $77.31
($70.14)
$ 111.0758%Sold Out0
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

CELG is held by these Gurus:

Ticker Guru Name Portfolio Date* Current Shares % of Shares Outstanding % of Total Assets Managed Change from Last Holdings Holding History
CELG John Hussman 2014-09-3025,00000.2New Buy
CELG Ken Fisher 2014-09-30232,1370.030.05+77.12%
CELG Mario Gabelli 2014-09-3025,76000.01+11.42%
CELG Ronald Muhlenkamp 2014-09-30146,9400.022.5+1.94%
CELG George Soros 2014-09-30000Sold Out
CELG Joel Greenblatt 2014-09-30000Sold Out
Premium Most recent portfolio changes are included for Premium Members only!


CELG: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
KARSEN PERRY Asee remarks 2014-11-12Sell39,420$107.232.97view
HUGIN ROBERT Jsee remarks 2014-11-03Sell158,000$106.683.5view
MARIO ERNESTDirector 2014-10-27Sell100,000$102.857.35view
CASEY MICHAEL DDirector 2014-10-24Sell15,000$102.947.26view
KAPLAN GILLADirector 2014-09-08Sell30,000$93.7317.8view
LOUGHLIN JAMES JDirector 2014-08-22Sell20,000$91.2521view
CASEY MICHAEL DDirector 2014-08-14Sell30,000$88.5924.63view
KARSEN PERRY Asee remarks 2014-08-04Sell39,104$87.5526.11view
Smith Scott AndrewSee Remarks 2014-08-01Sell0$026.11view
BARKER RICHARD WDirector 2014-07-25Sell17,600$87.0326.86view

Press Releases about CELG :

    Quarterly/Annual Reports about CELG:

    News about CELG:

    Articles On GuruFocus.com
    UPDATE: Bionor Pharma Announces That the Combination of Vacc-4x + Revlimid(R) Is Well Tolerated and Nov 18 2014 
    Bionor Pharma Announces That the Combination of Vacc-4x + Revlimid(R) Is Safe and Increases CD4 Coun Nov 17 2014 
    Three Attractively Priced Small Cap Biotech Stocks Nov 05 2014 
    Weekly 52-Week Highs Highlight: ALL, SRE, CLX, CELG Oct 05 2014 
    Ken Fisher's Top Increases of the First Quarter Apr 22 2014 
    David Winters' 2013 Letter to Wintergreen Fund Shareholders Mar 05 2014 
    You Can No Longer Ignore Biotech Feb 07 2014 
    Trying to Beat the Market Is a Fool’s Errand Oct 17 2013 
    Insiders Are Buying Idera Pharmaceuticals Sep 19 2013 
    comment on CELG Mar 20 2013 


    More From Other Websites
    5 Trade Ideas for Celgene this Week Nov 24 2014
    Alibaba Among 5 Top Stocks With Top Profit Margins Nov 23 2014
    Cramer: Stick with what's working Nov 21 2014
    AbbVie, Celgene, Sanofi Drugs Get EU Endorsements Nov 21 2014
    Trade-Ideas: Celgene (CELG) Is Today's Momo Momentum Stock Nov 21 2014
    Celgene Receives Positive CHMP Opinion for OTEZLA® (apremilast), the First Oral PDE4 Inhibitor for... Nov 21 2014
    Europe gives green light to AbbVie hepatitis C medicine, others Nov 21 2014
    Celgene Receives Positive CHMP Opinion for OTEZLA® (apremilast), the First Oral PDE4 Inhibitor for... Nov 21 2014
    Chef Michael Ferraro, the Pancreatic Cancer Action Network and Meals to Heal Team up with Celgene to... Nov 20 2014
    Celgene Up on Encouraging Long-Term Phase III Otezla Data Nov 19 2014
    Cramer shares hazards of skepticism Nov 18 2014
    Oral OTEZLA® (Apremilast) Showed Sustained Clinical Response over Two Years in Patients with Active... Nov 18 2014
    UPDATE: Bionor Pharma Announces That the Combination of Vacc-4x + Revlimid(R) Is Well Tolerated and... Nov 18 2014
    Bionor Pharma Announces That the Combination of Vacc-4x + Revlimid(R) Is Safe and Increases CD4... Nov 17 2014
    Biotech correction coming? 16 trades, 55 seconds Nov 14 2014
    Stock Market Treads Water; Earnings Drive BitAuto Nov 14 2014
    Stocks Drift Lower As Biotechs Tumble Nov 14 2014
    Stocks Mixed; Amazon Jumps On Book Deal Nov 14 2014
    Stocks Flat While Medical Issues Tumble Nov 14 2014
    Celgene Is Up 22% Over The Past Month; What Do Technicians Think? Nov 13 2014

    Add Notes, Comments

    If you want to ask a question, or report a bug, please create a support ticket.

    User Comments

    No comment yet
    Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
    GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
    Free 7-day Trial
    FEEDBACK